BOSTON — In the staging of liver fibrosis in the post-liver transplant setting, readings from noninvasive tests commonly have major discrepancies when compared with liver biopsy results, particularly ...
Please provide your email address to receive an email when new articles are posted on . Noninvasive tests for liver fibrosis screening performed worse among Black adults vs. other racial-ethnic groups ...
Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO—a certified algorithm ...
An intelligent liver function test platform (iLFT) successfully integrated into one Scottish primary care system reduced unnecessary specialist referrals over a 5-year period, and improved triage for ...
Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...
Hypertension in men and an increasing number of cardiometabolic criteria were associated with higher risk for advanced fibrosis and at-risk MASH.
D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive top-line 48-week ...
The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...
An AI-powered blood test that analyzes DNA fragments could detect silent liver disease long before symptoms begin.
Please provide your email address to receive an email when new articles are posted on . After screening, excessive drinking decreased from 46% to 32% at 6 months among those at risk for ALD. After 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results